
Translate Bio, Inc. Revenue 2011-2026 | TBIO
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Translate Bio, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 139 M | 7.8 M | 1.42 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 139 M | 1.42 M | 49.3 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M | ||
|
AbCellera Biologics
ABCL
|
75.1 M | $ 3.57 | 0.14 % | $ 1.07 B | ||
|
Acorda Therapeutics
ACOR
|
118 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
100 M | - | 4.01 % | $ 150 M | ||
|
Advaxis
ADXS
|
13 K | - | -9.65 % | $ 45.9 M | ||
|
AC Immune SA
ACIU
|
27.3 M | $ 3.26 | 4.15 % | $ 229 M | ||
|
I-Mab
IMAB
|
88 M | - | - | $ 866 M | ||
|
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | ||
|
AgeX Therapeutics
AGE
|
142 K | - | -10.17 % | $ 12.2 K | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | ||
|
Albireo Pharma
ALBO
|
40.6 M | - | -0.23 % | $ 916 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | ||
|
ADC Therapeutics SA
ADCT
|
2.34 M | $ 4.13 | -2.13 % | $ 105 M | ||
|
Aptorum Group Limited
APM
|
912 K | $ 0.79 | 0.04 % | $ 4.31 M | ||
|
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
82 M | $ 6.45 | -2.71 % | $ 177 M | ||
|
Adverum Biotechnologies
ADVM
|
1 M | - | - | $ 86.2 M | ||
|
argenx SE
ARGX
|
36.4 M | $ 708.53 | 0.74 % | $ 25 B | ||
|
Alterity Therapeutics Limited
ATHE
|
109 K | $ 3.43 | -4.99 % | $ 8.25 B | ||
|
Ascendis Pharma A/S
ASND
|
720 M | $ 229.59 | -0.62 % | $ 5 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
325 K | - | - | $ 26.5 M | ||
|
BioCardia
BCDA
|
477 K | $ 1.3 | 2.36 % | $ 27.5 M | ||
|
Atea Pharmaceuticals
AVIR
|
351 M | $ 6.08 | 0.5 % | $ 495 M | ||
|
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - | ||
|
Athersys
ATHX
|
5.51 M | - | 3.77 % | $ 22.4 M | ||
|
Acer Therapeutics
ACER
|
1.26 M | - | 2.71 % | $ 14 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
853 K | $ 3.49 | -2.51 % | $ 7.59 B | ||
|
Catalyst Biosciences
CBIO
|
117 M | $ 11.08 | -4.32 % | $ 990 M | ||
|
Aeterna Zentaris
AEZS
|
9.59 M | - | 5.93 % | $ 314 M | ||
|
AlloVir
ALVR
|
165 K | - | 4.14 % | $ 49.1 M | ||
|
Anika Therapeutics
ANIK
|
167 M | $ 14.49 | 0.91 % | $ 212 M | ||
|
Aptinyx
APTX
|
1 M | - | -39.0 % | $ 4.57 M | ||
|
AVEO Pharmaceuticals
AVEO
|
42.3 M | - | - | $ 521 M | ||
|
Ayala Pharmaceuticals
AYLA
|
692 K | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
66.4 M | $ 2.6 | -1.52 % | $ 16.3 M | ||
|
Autolus Therapeutics plc
AUTL
|
242 K | $ 1.51 | -0.33 % | $ 385 M | ||
|
BioNTech SE
BNTX
|
482 M | $ 94.7 | 4.59 % | $ 27.2 B | ||
|
CureVac N.V.
CVAC
|
48.9 M | - | - | $ 867 M | ||
|
Aravive
ARAV
|
9.14 M | - | -13.39 % | $ 1.45 M |